Global Context and Update Joint UNICEF, UNFPA and WHO meeting with manufacturers and suppliers

Bashier Enoos Department of Noncommunicable Diseases, Rehabilitation and Disability (NCD)





Global burden of noncommunicable diseases (NCDs)

75% of all non-pandemic related deaths are due to NCDs



Cardiovascular diseases cause 1 in 3 deaths

Chronic respiratory diseases cause 1 in 13 deaths



Cancers cause 1 in 6 deaths



Diabetes causes 1 in 28 deaths



NCDs are an urgent equity crisis

Every year 17 million people under the age of 70 die of NCDs, 86% of whom live in low- and middle-income countries



30% likelihood	
20% likelihood	
10% likelihood	
9%: Norway	29%: Cote d'Ivoire

Time to turn the tide on NCDs and mental health

The world is offtrack to meet NCD and mental health targets

G

2

- Despite UNHLMs in 2011, 2014 and 2018, the world is still off-track to meet NCD and mental health targets.
- The fourth high-level meeting in 2025 offers a unique opportunity for Member States to adopt a <u>bold</u>, <u>achievable agenda on NCDs and mental</u> <u>health towards 2030 and 2050.</u>



Key thematic areas

Engage	Invest	Align	Accelerate	Account
Enhancing governance	Sustainable financing	Creating health- promoting environments	Investing in primary health care and health system strengthening	Strengthening data and surveillance
 Multi-sectoral response Multistakeholder action Meaningful engagement of people with lived experience and communities Rights-based solutions 	 Domestic financing Win-win fiscal policies Development aid Funding platforms Cost-effective interventions Multidimensional Vulnerability Index (MVI) Out-of-pocket expenditure 	 Healthy diet Physical activity Tobacco Harmful use of alcohol Social, environmental and commercial determinants Advertising, taxation Climate change Food systems 	 Multi-morbidities Person-centred care PHC Access to medicines Health workforce Technology and innovation in healthcare Emergency risk reduction 	 Research Surveillance systems Reporting on NCD targets Revisiting NCD global monitoring framework



Updates relating to asthma and COPD

- Ongoing update of paediatric asthma guidelines to be published in 2025
 - Discussing recommendations for ipratropium bromide in management of acute asthma (already on EML for asthma, but not EMLc)
 - Discussing recommendations for IV magnesium sulphate in management of acute asthma (on EML for eclampsia/severe pre-eclampsia)
- Planned update to adult asthma and COPD guidelines to start in 2025, over next 2 years
 - Will consider combination inhalers (steroid plus fast-onset long-acting beta-agonist) for asthma (already on EML for asthma, but no WHO guidance on use)
- Irrespective of any new recommendations: Ongoing need to improve access to safe, effective quality and affordable medicines for CRDs – particularly inhaled medicines already on EML/EMLc and included in WHO Package of essential NCD interventions (PEN)



Cancer updates: childhood cancer

- Practice briefs (guidance on treatment standards) for childhood cancer to be published in 2025
 - Recommendations to align with current EML/EMLc and EDL
- Global Platform for access to childhood cancer medicines (WHO, St Jude Children's Research Hospital, UNICEF + PAHO Strategic Fund) – catalogue of approx. 35 products and 55 formulations being finalized
 - Products in line with EMLc
 - Shipments expected Q1 2025 with launch planned on 4 Feb 2025
 - Additional workstreams related to forecasting/supply planning, PQ, facilitated regulatory pathways (eg, SRA-CRP), PV being built out
- Strategic opportunity for market shaping including new product formulations (PADO process complete, dialogue on TPPs ongoing)



Cancer updates: cervical and breast cancers (as part of broader cancer control)

- Cervical cancer living guidelines for secondary prevention ongoing
 - Recommendations linked to PQ technologies including technical specifications
 - TPPs also produced for cervical cancer screening primary screening (*link below*)
 - Management/Implementation guidance anticipated to be published in 2025
- Breast cancer guidance on management anticipated in 2026
 - Procurement support in AFRO for essential technologies for breast cancer diagnosis in primary care
 - PQ available for trastuzumab (essential medicine)
 - Strategic partner dialogue organized on market shaping (Q3 2024) with workstream initiation in 2025
- WHO operational guidance and procurement support for cancer centres linked to recent joint WHO-IAEA publication (link below)
 - Active support planned/ongoing in 6 countries with MDBx funding



https://www.who.int/publications/i/item/9789240100275 https://www.iaea.org/publications/15493/guidance-on-setting-up-a-comprehensive-cancer-centre

Target product profiles for human papillomavirus screening tests to detect cervical pre-cancer and cancer



Guidance on Setting Up a Comprehensive Cancer Centre

CVD / Hypertension

- Integrating HIV and hypertension care for enhanced health outcome <u>Integrating HIV and hypertension care for enhanced</u> <u>health outcome</u>
- Framework for Acute Coronary Syndrome and Stroke (early 2025)
- Guidelines on management of dyslipidaemia (with Diabetes team 2025)
- White paper (Advocacy Brie) on the Use of Validated Automated BP Devices (June 2025)



Updates relating Diabetes

- Guidelines on management of type 1 diabetes in children / and adults ongoing
- Guidelines on management of type 2 diabetes
- Guidelines on management of hyperglycaemia in pregnancy (Maternal/Perinatal Team)
- Guidelines on GLP-1 receptor agonists for obesity (Nutrition/Food Safety team)
- Report on age-appropriateness of EMLc medicines for diabetes and hypoglycaemia
- All for 2025



Technical specification series for HbA1c analysers and blood glucose meters



Haemoglobin A1c point of
care analysers for

profession



Technical specifications series fo prequalification – diagnostic asse

> Technical specifications series for submission to WHO prequalification – diagnostic assessment



In-vitro diagnostic medical devices for monitoring of blood glucose in capillary blood The PQ IVD assessment team hosted a webinar on 20 March 2024 for manufacturers of HbA1c point of care analysers and BGMS to provide an update on the expansion of the scope for prequalification of IVDs.



Requests for Member States and all stakeholders

Engage in the preparatory process for the fourth high-level meeting on NCDs in 2025.

A. Participate in regular briefings and share feedback

B. Join the Multistakeholder hearing in ~May 2025 C. Advocate with New York missions to engage in negotiation process of the political declaration D. Advocate to Heads of State to attend the 4th Gathering of the Global Group of Heads of State for NCDs in 2025







Time to invest in bold, ambitious action on NCDs and mental health







Thank you

<u>Contact</u> Bashier Enoos Department of Noncommunicable Diseases, Rehabilitation and Disability (NCD) <u>enoosb@who.int</u>

